ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Personalized Medicine and Epigenomics Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-3R9627
Home | Market Reports | Business & Industrial| Industrial Materials & Equipment| Heavy Machinery
Global Personalized Medicine and Epigenomics Market Insights Forecast to 2028
BUY CHAPTERS

Global Personalized Medicine and Epigenomics Market Research Report 2025

Code: QYRE-Auto-3R9627
Report
August 2025
Pages:113
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Abbott Laboratories
Affymetrix Inc
Agilent Technologies
Astellas Pharmaceuticals
Bayer
Bio Vision
Celgene Corp
EMD Millipore
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
GlaxoSmithKline PLC
Illumina Inc
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
Les Laboratoires Servier
Merck
NatureWise Biotech & Medicals Corp
Novartis Pharma Ag
Oncolys BioPharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Epigenomics

Personalized Medicine and Epigenomics Market Size

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.

Personalized Medicine and Epigenomics Market

Personalized Medicine and Epigenomics Market

The global market for Personalized Medicine and Epigenomics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine and Epigenomics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine and Epigenomics.
The Personalized Medicine and Epigenomics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Personalized Medicine and Epigenomics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalized Medicine and Epigenomics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Personalized Medicine and Epigenomics Market Report

Report Metric Details
Report Name Personalized Medicine and Epigenomics Market
Accounted market size in year US$ 603 billion
CAGR 5%
Base Year year
Segment by Type
  • Reagents
  • Kits
  • Instruments
  • Enzymes
  • Services
Segment by Application
  • Oncology
  • Non-Oncology
  • Cancer Drug Technology
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, BAYER AG, Bio Vision, Celgene Corp., Emd Millipore, Epigenomics AG, Epigentex, Envivo Pharmaceuticals (Forum Pharmaceutricals), Gilead Sciences, Glaxosmithkline, Illumina Inc., Johnson & Johnson, Karus Therapeutics Limited, Laboratory Corp. Of America Holdings, LES Laboratoires Servier, Merck, Naturewise Biotech & Medicals Corp., Novartis Pharma AG, Oncolys Biopharma Inc., Orchid Chemicals & Pharmaceuticals Limited, Progen Pharmaceuticals Limited, Quest Diagnostics, Roche Holding AG, Rubicon Genomics, Takeda Pharmaceutical Company Limited
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Personalized Medicine and Epigenomics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Personalized Medicine and Epigenomics Market report?

Ans: The main players in the Personalized Medicine and Epigenomics Market are Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, BAYER AG, Bio Vision, Celgene Corp., Emd Millipore, Epigenomics AG, Epigentex, Envivo Pharmaceuticals (Forum Pharmaceutricals), Gilead Sciences, Glaxosmithkline, Illumina Inc., Johnson & Johnson, Karus Therapeutics Limited, Laboratory Corp. Of America Holdings, LES Laboratoires Servier, Merck, Naturewise Biotech & Medicals Corp., Novartis Pharma AG, Oncolys Biopharma Inc., Orchid Chemicals & Pharmaceuticals Limited, Progen Pharmaceuticals Limited, Quest Diagnostics, Roche Holding AG, Rubicon Genomics, Takeda Pharmaceutical Company Limited

What are the Application segmentation covered in the Personalized Medicine and Epigenomics Market report?

Ans: The Applications covered in the Personalized Medicine and Epigenomics Market report are Oncology, Non-Oncology, Cancer Drug Technology

What are the Type segmentation covered in the Personalized Medicine and Epigenomics Market report?

Ans: The Types covered in the Personalized Medicine and Epigenomics Market report are Reagents, Kits, Instruments, Enzymes, Services

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2020-2031)
2.2 Global Personalized Medicine and Epigenomics Growth Trends by Region
2.2.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Personalized Medicine and Epigenomics Historic Market Size by Region (2020-2025)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Region (2026-2031)
2.3 Personalized Medicine and Epigenomics Market Dynamics
2.3.1 Personalized Medicine and Epigenomics Industry Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2020-2025)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2020-2025)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2024
3.5 Global Key Players of Personalized Medicine and Epigenomics Head office and Area Served
3.6 Global Key Players of Personalized Medicine and Epigenomics, Product and Application
3.7 Global Key Players of Personalized Medicine and Epigenomics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2020-2025)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2026-2031)
5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2020-2025)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2020-2031)
6.2 North America Personalized Medicine and Epigenomics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Personalized Medicine and Epigenomics Market Size by Country (2020-2025)
6.4 North America Personalized Medicine and Epigenomics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2020-2031)
7.2 Europe Personalized Medicine and Epigenomics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Personalized Medicine and Epigenomics Market Size by Country (2020-2025)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2020-2031)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2020-2025)
8.4 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2020-2031)
9.2 Latin America Personalized Medicine and Epigenomics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Country (2020-2025)
9.4 Latin America Personalized Medicine and Epigenomics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2020-2031)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2020-2025)
10.4 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix
11.2.1 Affymetrix Company Details
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.2.5 Affymetrix Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.3.5 Agilent Technologies Recent Development
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Details
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.4.5 Astellas Pharmaceuticals Recent Development
11.5 BAYER AG
11.5.1 BAYER AG Company Details
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.5.5 BAYER AG Recent Development
11.6 Bio Vision
11.6.1 Bio Vision Company Details
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.6.5 Bio Vision Recent Development
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Details
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.7.5 Celgene Corp. Recent Development
11.8 Emd Millipore
11.8.1 Emd Millipore Company Details
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.8.5 Emd Millipore Recent Development
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Details
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.9.5 Epigenomics AG Recent Development
11.10 Epigentex
11.10.1 Epigentex Company Details
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.10.5 Epigentex Recent Development
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Details
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.12.5 Gilead Sciences Recent Development
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Details
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.13.5 Glaxosmithkline Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Details
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.14.5 Illumina Inc. Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Details
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.15.5 Johnson & Johnson Recent Development
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Details
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.16.5 Karus Therapeutics Limited Recent Development
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Details
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.17.5 Laboratory Corp. Of America Holdings Recent Development
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Details
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.18.5 LES Laboratoires Servier Recent Development
11.19 Merck
11.19.1 Merck Company Details
11.19.2 Merck Business Overview
11.19.3 Merck Personalized Medicine and Epigenomics Introduction
11.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.19.5 Merck Recent Development
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Details
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Details
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.21.5 Novartis Pharma AG Recent Development
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Details
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.22.5 Oncolys Biopharma Inc. Recent Development
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Details
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.24.5 Progen Pharmaceuticals Limited Recent Development
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Details
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.25.5 Quest Diagnostics Recent Development
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Details
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.26.5 Roche Holding AG Recent Development
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Details
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.27.5 Rubicon Genomics Recent Development
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Details
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025)
11.28.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Abbott Laboratories
Affymetrix Inc
Agilent Technologies
Astellas Pharmaceuticals
Bayer
Bio Vision
Celgene Corp
EMD Millipore
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
GlaxoSmithKline PLC
Illumina Inc
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
Les Laboratoires Servier
Merck
NatureWise Biotech & Medicals Corp
Novartis Pharma Ag
Oncolys BioPharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Epigenomics
List of Tables
 Table 1. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Reagents
 Table 3. Key Players of Kits
 Table 4. Key Players of Instruments
 Table 5. Key Players of Enzymes
 Table 6. Key Players of Services
 Table 7. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Personalized Medicine and Epigenomics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Personalized Medicine and Epigenomics Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Personalized Medicine and Epigenomics Market Share by Region (2020-2025)
 Table 11. Global Personalized Medicine and Epigenomics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Personalized Medicine and Epigenomics Market Share by Region (2026-2031)
 Table 13. Personalized Medicine and Epigenomics Market Trends
 Table 14. Personalized Medicine and Epigenomics Market Drivers
 Table 15. Personalized Medicine and Epigenomics Market Challenges
 Table 16. Personalized Medicine and Epigenomics Market Restraints
 Table 17. Global Personalized Medicine and Epigenomics Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Personalized Medicine and Epigenomics Market Share by Players (2020-2025)
 Table 19. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2024)
 Table 20. Ranking of Global Top Personalized Medicine and Epigenomics Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Personalized Medicine and Epigenomics Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Personalized Medicine and Epigenomics, Headquarters and Area Served
 Table 23. Global Key Players of Personalized Medicine and Epigenomics, Product and Application
 Table 24. Global Key Players of Personalized Medicine and Epigenomics, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Personalized Medicine and Epigenomics Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2020-2025)
 Table 28. Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2026-2031)
 Table 30. Global Personalized Medicine and Epigenomics Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2020-2025)
 Table 32. Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2026-2031)
 Table 34. North America Personalized Medicine and Epigenomics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Personalized Medicine and Epigenomics Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Personalized Medicine and Epigenomics Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Personalized Medicine and Epigenomics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Personalized Medicine and Epigenomics Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Personalized Medicine and Epigenomics Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Personalized Medicine and Epigenomics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Personalized Medicine and Epigenomics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Personalized Medicine and Epigenomics Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Personalized Medicine and Epigenomics Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Personalized Medicine and Epigenomics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Abbott Laboratories Company Details
 Table 50. Abbott Laboratories Business Overview
 Table 51. Abbott Laboratories Personalized Medicine and Epigenomics Product
 Table 52. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 53. Abbott Laboratories Recent Development
 Table 54. Affymetrix Company Details
 Table 55. Affymetrix Business Overview
 Table 56. Affymetrix Personalized Medicine and Epigenomics Product
 Table 57. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 58. Affymetrix Recent Development
 Table 59. Agilent Technologies Company Details
 Table 60. Agilent Technologies Business Overview
 Table 61. Agilent Technologies Personalized Medicine and Epigenomics Product
 Table 62. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 63. Agilent Technologies Recent Development
 Table 64. Astellas Pharmaceuticals Company Details
 Table 65. Astellas Pharmaceuticals Business Overview
 Table 66. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
 Table 67. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 68. Astellas Pharmaceuticals Recent Development
 Table 69. BAYER AG Company Details
 Table 70. BAYER AG Business Overview
 Table 71. BAYER AG Personalized Medicine and Epigenomics Product
 Table 72. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 73. BAYER AG Recent Development
 Table 74. Bio Vision Company Details
 Table 75. Bio Vision Business Overview
 Table 76. Bio Vision Personalized Medicine and Epigenomics Product
 Table 77. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 78. Bio Vision Recent Development
 Table 79. Celgene Corp. Company Details
 Table 80. Celgene Corp. Business Overview
 Table 81. Celgene Corp. Personalized Medicine and Epigenomics Product
 Table 82. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 83. Celgene Corp. Recent Development
 Table 84. Emd Millipore Company Details
 Table 85. Emd Millipore Business Overview
 Table 86. Emd Millipore Personalized Medicine and Epigenomics Product
 Table 87. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 88. Emd Millipore Recent Development
 Table 89. Epigenomics AG Company Details
 Table 90. Epigenomics AG Business Overview
 Table 91. Epigenomics AG Personalized Medicine and Epigenomics Product
 Table 92. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 93. Epigenomics AG Recent Development
 Table 94. Epigentex Company Details
 Table 95. Epigentex Business Overview
 Table 96. Epigentex Personalized Medicine and Epigenomics Product
 Table 97. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 98. Epigentex Recent Development
 Table 99. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
 Table 100. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
 Table 101. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product
 Table 102. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 103. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
 Table 104. Gilead Sciences Company Details
 Table 105. Gilead Sciences Business Overview
 Table 106. Gilead Sciences Personalized Medicine and Epigenomics Product
 Table 107. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 108. Gilead Sciences Recent Development
 Table 109. Glaxosmithkline Company Details
 Table 110. Glaxosmithkline Business Overview
 Table 111. Glaxosmithkline Personalized Medicine and Epigenomics Product
 Table 112. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 113. Glaxosmithkline Recent Development
 Table 114. Illumina Inc. Company Details
 Table 115. Illumina Inc. Business Overview
 Table 116. Illumina Inc. Personalized Medicine and Epigenomics Product
 Table 117. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 118. Illumina Inc. Recent Development
 Table 119. Johnson & Johnson Company Details
 Table 120. Johnson & Johnson Business Overview
 Table 121. Johnson & Johnson Personalized Medicine and Epigenomics Product
 Table 122. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 123. Johnson & Johnson Recent Development
 Table 124. Karus Therapeutics Limited Company Details
 Table 125. Karus Therapeutics Limited Business Overview
 Table 126. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product
 Table 127. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 128. Karus Therapeutics Limited Recent Development
 Table 129. Laboratory Corp. Of America Holdings Company Details
 Table 130. Laboratory Corp. Of America Holdings Business Overview
 Table 131. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product
 Table 132. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 133. Laboratory Corp. Of America Holdings Recent Development
 Table 134. LES Laboratoires Servier Company Details
 Table 135. LES Laboratoires Servier Business Overview
 Table 136. LES Laboratoires Servier Personalized Medicine and Epigenomics Product
 Table 137. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 138. LES Laboratoires Servier Recent Development
 Table 139. Merck Company Details
 Table 140. Merck Business Overview
 Table 141. Merck Personalized Medicine and Epigenomics Product
 Table 142. Merck Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 143. Merck Recent Development
 Table 144. Naturewise Biotech & Medicals Corp. Company Details
 Table 145. Naturewise Biotech & Medicals Corp. Business Overview
 Table 146. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product
 Table 147. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 148. Naturewise Biotech & Medicals Corp. Recent Development
 Table 149. Novartis Pharma AG Company Details
 Table 150. Novartis Pharma AG Business Overview
 Table 151. Novartis Pharma AG Personalized Medicine and Epigenomics Product
 Table 152. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 153. Novartis Pharma AG Recent Development
 Table 154. Oncolys Biopharma Inc. Company Details
 Table 155. Oncolys Biopharma Inc. Business Overview
 Table 156. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product
 Table 157. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 158. Oncolys Biopharma Inc. Recent Development
 Table 159. Orchid Chemicals & Pharmaceuticals Limited Company Details
 Table 160. Orchid Chemicals & Pharmaceuticals Limited Business Overview
 Table 161. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
 Table 162. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 163. Orchid Chemicals & Pharmaceuticals Limited Recent Development
 Table 164. Progen Pharmaceuticals Limited Company Details
 Table 165. Progen Pharmaceuticals Limited Business Overview
 Table 166. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
 Table 167. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 168. Progen Pharmaceuticals Limited Recent Development
 Table 169. Quest Diagnostics Company Details
 Table 170. Quest Diagnostics Business Overview
 Table 171. Quest Diagnostics Personalized Medicine and Epigenomics Product
 Table 172. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 173. Quest Diagnostics Recent Development
 Table 174. Roche Holding AG Company Details
 Table 175. Roche Holding AG Business Overview
 Table 176. Roche Holding AG Personalized Medicine and Epigenomics Product
 Table 177. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 178. Roche Holding AG Recent Development
 Table 179. Rubicon Genomics Company Details
 Table 180. Rubicon Genomics Business Overview
 Table 181. Rubicon Genomics Personalized Medicine and Epigenomics Product
 Table 182. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 183. Rubicon Genomics Recent Development
 Table 184. Takeda Pharmaceutical Company Limited Company Details
 Table 185. Takeda Pharmaceutical Company Limited Business Overview
 Table 186. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product
 Table 187. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2020-2025) & (US$ Million)
 Table 188. Takeda Pharmaceutical Company Limited Recent Development
 Table 189. Research Programs/Design for This Report
 Table 190. Key Data Information from Secondary Sources
 Table 191. Key Data Information from Primary Sources
 Table 192. Authors List of This Report


List of Figures
 Figure 1. Personalized Medicine and Epigenomics Picture
 Figure 2. Global Personalized Medicine and Epigenomics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Personalized Medicine and Epigenomics Market Share by Type: 2024 VS 2031
 Figure 4. Reagents Features
 Figure 5. Kits Features
 Figure 6. Instruments Features
 Figure 7. Enzymes Features
 Figure 8. Services Features
 Figure 9. Global Personalized Medicine and Epigenomics Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Personalized Medicine and Epigenomics Market Share by Application: 2024 VS 2031
 Figure 11. Oncology Case Studies
 Figure 12. Non-Oncology Case Studies
 Figure 13. Cancer Drug Technology Case Studies
 Figure 14. Personalized Medicine and Epigenomics Report Years Considered
 Figure 15. Global Personalized Medicine and Epigenomics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Personalized Medicine and Epigenomics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Personalized Medicine and Epigenomics Market Share by Region: 2024 VS 2031
 Figure 18. Global Personalized Medicine and Epigenomics Market Share by Players in 2024
 Figure 19. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2024
 Figure 21. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Personalized Medicine and Epigenomics Market Share by Country (2020-2031)
 Figure 23. United States Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Personalized Medicine and Epigenomics Market Share by Country (2020-2031)
 Figure 27. Germany Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Region (2020-2031)
 Figure 35. China Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Personalized Medicine and Epigenomics Market Share by Country (2020-2031)
 Figure 43. Mexico Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Country (2020-2031)
 Figure 47. Turkey Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Personalized Medicine and Epigenomics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 51. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 52. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 53. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 54. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 55. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 56. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 57. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 58. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 59. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 60. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 61. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 62. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 63. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 64. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 65. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 66. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 67. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 68. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 69. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 70. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 71. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 72. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 73. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 74. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 75. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 76. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 77. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2020-2025)
 Figure 78. Bottom-up and Top-down Approaches for This Report
 Figure 79. Data Triangulation
 Figure 80. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Reducer Elbows Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35L19946
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global High-Pressure Breathing Air Compressor for Diving and Firefighting Applications Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2K20269
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Steam Trap Valve Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37H9442
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Consumer-grade IP Robots Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21L19992
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions